Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Annexon Biosciences (NASDAQ: ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Douglas Love, the company's president and CEO, will deliver a presentation on June 4, 2025, at 8:10 a.m. EST. Investors and interested parties can access the live webcast through the 'Events & Presentations' section on Annexon's investor relations website. The presentation recording will remain available for replay on www.annexonbio.com for 30 days after the event.

News Market Reaction

-6.42%

1 alert

-6.42% News Effect

On the day this news was published, ANNX declined 6.42%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

FAQ

When is Annexon Biosciences (ANNX) presenting at the Jefferies Global Healthcare Conference?

Annexon Biosciences will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:10 a.m. EST.

Who will represent Annexon Biosciences (ANNX) at the Jefferies Healthcare Conference?

Douglas Love, president and chief executive officer of Annexon Biosciences, will present at the conference.

How can investors access Annexon Biosciences' (ANNX) presentation at the Jefferies conference?

Investors can access the live webcast through the 'Events & Presentations' section on Annexon's investor website at www.annexonbio.com.

How long will Annexon's (ANNX) presentation replay be available?

The webcast replay will be archived on Annexon's website for 30 days following the presentation.